# Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

> **NCT03708224** · PHASE2 · RECRUITING · sponsor: **Alain Algazi** · enrollment: 55 (estimated)

## Conditions studied

- Cancer
- Carcinoma
- Squamous Cell Carcinoma
- Head and Neck Cancer

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **BIOLOGICAL:** Tocilizumab
- **BIOLOGICAL:** Tiragolumab

## Key facts

- **NCT ID:** NCT03708224
- **Lead sponsor:** Alain Algazi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-03-08
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2025-01-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03708224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03708224, "Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03708224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*